EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Danaparoid Sodium (Orgaran®): An Update on its Approved Indications

Harry N Magnani, Rupert M Bauersachs, Stanislava Tzaneva

Journal of Cardiology and Cardiovascular Medicine · 13.08.2026 · 33-57

DOI: 10.29328/journal.jccm.1001228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiology and Cardiovascular Medicine, online erschienen am 13.08.2026. Verfasst von Harry N Magnani und 2 weiteren Autor:innen. Die Arbeit nennt 284 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This review updates the rationale for danaparoid use and the clinical outcomes reported for its approved indications, while identifying areas in which its use may be optimized. Danaparoid, a low-molecular-weight heparinoid, is approved for deep-vein thrombosis prophylaxis and for the treatment of heparin-induced thrombocytopenia (HIT) and disseminated intravascular coagulation (DIC). It consists predominantly of heparan sulphate, of which a small fraction mediates anti-Xa activity through Antithrombin binding, whereas the larger fraction contributes importantly to thrombin generation inhibition and appears to modulate the actions of anti-PF4/polyanion antibodies and attenuate inflammatory responses. These features distinguish danaparoid from other approved antithrombotic agents.

Methods

From an extensive literature search covering 1981 to 2026, new publications, particularly from Japan, have been identified that extend our knowledge of danaparoid.

Results

Despite established dosing recommendations and a substantial body of efficacy and safety data, the clinical value of danaparoid may be underestimated because its pharmacologic behaviour is often misunderstood. This can lead to inappropriate dosing choices. In addition, contraindications and warnings may discourage danaparoid use in clinical settings in which it has shown value. In Japan, the intermittent dosing regimen approved there for DIC has been used unmodified for routine prophylaxis and thrombosis treatment with mixed results. Because of the complex pharmacokinetics of danaparoid, this regimen may be inappropriate in situations where continuous thrombotic and anti-inflammatory protection is required and also for routine thrombosis prophylaxis.

Conclusion

Adopting the established separate dosing recommendations for thrombosis treatment and prophylaxis could improve clinical outcomes. In particular, the therapeutic regime of an intravenous loading bolus followed by continuous therapeutic infusion may better sustain the interactions between danaparoid’s active components and thereby optimise its anticoagulant and immune-modulatory effects.

Zitieren

APA

Magnani, H. N., Bauersachs, R. M., & Tzaneva, S. (2026). Danaparoid Sodium (Orgaran®): An Update on its Approved Indications. Journal of Cardiology and Cardiovascular Medicine, 33-57. https://doi.org/10.29328/journal.jccm.1001228

Vancouver

Magnani HN, Bauersachs RM, Tzaneva S. Danaparoid Sodium (Orgaran®): An Update on its Approved Indications. Journal of Cardiology and Cardiovascular Medicine. 2026:33-57. doi:10.29328/journal.jccm.1001228

BibTeX
@article{Magnani2026,
  author = {Magnani, Harry N and Bauersachs, Rupert M and Tzaneva, Stanislava},
  title = {Danaparoid Sodium (Orgaran®): An Update on its Approved Indications},
  journal = {Journal of Cardiology and Cardiovascular Medicine},
  year = {2026},
  pages = {33--57},
  doi = {10.29328/journal.jccm.1001228}
}
Kostenlos starten →